首页 > 市场调查报告书 > 製药

消化器

非酒精性脂肪性肝炎生物标记市场规模、份额和成长分析（按类型、最终用户和地区划分）—2026-2033年产业预测

市场调查报告书

商品编码

1897814

非酒精性脂肪性肝炎生物标记市场规模、份额和成长分析（按类型、最终用户和地区划分）—2026-2033年产业预测

Non-alcoholic Steatohepatitis Biomarkers Market Size, Share, and Growth Analysis, By Type (Hepatic Fibrosis Biomarkers, Serum Biomarkers), By End User (Research Institutes and Academics, Diagnostic Centres), By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

全球非酒精性脂肪性肝炎生物标记市场规模预计在 2024 年达到 13 亿美元，从 2025 年的 16.7 亿美元增长到 2033 年的 125.9 亿美元，在预测期（2026-2033 年）内复合年增长率为 28.7%。

全球非酒精性脂肪性肝炎（NASH）生物标记市场正经历强劲成长，这主要受NASH盛行率上升的推动。 NASH与肥胖和代谢紊乱密切相关。疾病发生率的上升推动了对精准生物标记的需求，这些标记对于早期诊断、监测疾病进展和评估治疗效果至关重要。生物标记对于识别高风险族群、区分NASH与其他肝臟疾病以及评估疾病严重程度至关重要。研发领域的进步，特别是新型生物标记的发现和非侵入性诊断工具的开发，也推动了市场的发展。这个快速成长的市场能够很好地满足对有效诊断和监测解决方案的迫切需求，并为基于生物标记的创新干预方法提供了巨大的机会。

全球非酒精性脂肪性肝炎生物标记市场驱动因素

全球非酒精性脂肪性肝炎 (NASH) 生物标记市场的主要驱动因素是这种肝臟疾病在全球范围内的日益普及。 NASH 会导致肝臟脂肪堆积，进而引发发炎和损伤。肥胖率上升、久坐不动的生活方式和不健康的饮食习惯等因素都加剧了 NASH 的发病率。因此，人们越来越需要可靠的生物标记来有效诊断疾病、监测其进展并评估治疗效果。随着人们对该疾病的认识不断提高，以及认识到改进诊断解决方案至关重要，对 NASH 生物标记的需求持续激增。

影响全球非酒精性脂肪性肝炎生物标记市场的因素

全球非酒精性脂肪性肝炎 (NASH) 生物标记市场面临的主要挑战之一是缺乏标准化的生物标记和监管障碍。用于诊断和监测 NASH 的生物标记的开发和检验是一个复杂的过程，这使得它们的广泛应用难以实现。生物标记选择和应用方面缺乏共识进一步加剧了这个问题，阻碍了它们在临床实践中的广泛应用。此外，监管机构严格的检验要求对企业而言既耗时又昂贵。透过进一步的研究、标准化和完善监管指导来应对这些挑战，对于充分发挥 NASH 生物标记在改善患者预后方面的潜力至关重要。

全球非酒精性脂肪性肝炎生物标记市场趋势

全球非酒精性脂肪性肝炎 (NASH) 生物标记市场的一个显着趋势是，人们越来越关注非侵入性诊断方法。鑑于 NASH 的复杂性和进行性性，及时准确的诊断对于有效的疾病管理和治疗至关重要。非侵入性生物标记，包括血液检测和先进的影像学技术，因其优于传统侵入性肝臟切片检查的优势而日益普及，这些优势包括减轻患者负担、节省成本和普及性。这种向可靠且便利的诊断工具的转变不仅有望改善患者预后，还能提高临床试验的效率，从而推动 NASH 生物标记市场的成长。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Genfit SA（France）
Gilead Sciences, Inc.（United States）
Novartis AG（Switzerland）
Pfizer Inc.（United States）
Siemens Healthineers AG（Germany）
Bio-Rad Laboratories, Inc.（United States）
Abbott Laboratories（United States）
Prometheus Laboratories Inc.（United States）
NGM Biopharmaceuticals, Inc.（United States）
Metabolon, Inc.（United States）
Perspectum Ltd（United Kingdom）
Precision Medicine Group, Inc.（United States）
Grifols, SA（Spain）
Hologic, Inc.（United States）
Quest Diagnostics Incorporated（United States）
F. Hoffmann-La Roche Ltd（Switzerland）
Biopredictive（France）

结论与建议

简介目录

Product Code: SQMIG35A2593

Global Non-alcoholic Steatohepatitis Biomarkers Market size was valued at USD 1.3 Billion in 2024 and is poised to grow from USD 1.67 Billion in 2025 to USD 12.59 Billion by 2033, growing at a CAGR of 28.7% during the forecast period (2026-2033).

The Global Non-alcoholic Steatohepatitis (NASH) Biomarkers market is experiencing robust growth, driven by the rising prevalence of NASH linked to obesity and metabolic disorders. As the disease incidence escalates, there is an increasing demand for precise biomarkers essential for early diagnosis, monitoring disease progression, and evaluating therapeutic responses. Biomarkers are vital for identifying individuals at risk, distinguishing NASH from other liver diseases, and assessing severity levels. The market is also benefiting from advancements in research and development, particularly the identification of novel biomarkers and the creation of non-invasive diagnostic tools. This burgeoning market is well-positioned to meet the critical need for effective diagnostic and monitoring solutions, presenting substantial opportunities for innovative biomarker-based interventions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-alcoholic Steatohepatitis Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Non-alcoholic Steatohepatitis Biomarkers Market Segments Analysis

Global Non-alcoholic SteatohepatitisbiomarkersMarket is segmented by Type, End User and region. Based on Type, the market is segmented into Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers and Others. Based on End User, the market is segmented into Research Institutes and Academics, Diagnostic Centres, Pharmaceutical Companies and CROs, Hospitals and Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Non-alcoholic Steatohepatitis Biomarkers Market

A significant driver of the global Non-alcoholic Steatohepatitis (NASH) biomarkers market is the increasing global prevalence of this liver condition, characterized by fat accumulation in the liver leading to inflammation and damage. Factors such as rising obesity rates, sedentary lifestyles, and poor dietary choices are contributing to the heightened occurrence of NASH. Consequently, there is a growing necessity for reliable biomarkers that can effectively diagnose the disease, monitor its progression, and evaluate treatment responses. The demand for NASH biomarkers continues to surge, fueled by heightened awareness of the condition and the imperative for enhanced diagnostic solutions.

Restraints in the Global Non-alcoholic Steatohepatitis Biomarkers Market

One of the major challenges facing the Global Non-alcoholic Steatohepatitis (NASH) Biomarkers market is the absence of standardized biomarkers alongside regulatory hurdles. The intricate processes involved in the development and validation of these biomarkers for diagnosing and monitoring NASH contribute to the difficulty in achieving broad acceptance. A lack of agreement on the selection and application of biomarkers further complicates matters, making it hard for them to gain traction in clinical settings. Moreover, the stringent validation requirements set by regulatory bodies can be both time-consuming and expensive for companies. Addressing these issues through further research, standardization, and improved regulatory guidance is essential for realizing the full potential of NASH biomarkers in enhancing patient outcomes.

Market Trends of the Global Non-alcoholic Steatohepatitis Biomarkers Market

A prominent trend in the Global Non-alcoholic Steatohepatitis (NASH) Biomarkers market is the escalating emphasis on non-invasive diagnostic methodologies. Given the intricate nature and progressive characteristics of NASH, timely and precise diagnosis is essential for effective disease management and treatment. Non-invasive biomarkers, including blood-based tests and advanced imaging techniques, are gaining popularity due to their advantages over traditional invasive liver biopsies, such as minimizing patient discomfort, lowering costs, and facilitating broader accessibility. This shift towards reliable and convenient diagnostic tools not only promises to improve patient outcomes but also enhances the efficiency of clinical trials, propelling the growth of the NASH biomarkers market.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technological Advancement

Global Non-alcoholic Steatohepatitis Biomarkers Market Size by Type & CAGR (2026-2033)

Market Overview
Hepatic Fibrosis Biomarkers
Serum Biomarkers
Oxidative Stress Biomarkers
Apoptosis Biomarkers
Others

Global Non-alcoholic Steatohepatitis Biomarkers Market Size by End User & CAGR (2026-2033)

Market Overview
Research Institutes and Academics
Diagnostic Centres
Pharmaceutical Companies and CROs
Hospitals and Clinics
Others

Global Non-alcoholic Steatohepatitis Biomarkers Market Size & CAGR (2026-2033)

North America (Type, End User)
- US
- Canada
Europe (Type, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Genfit SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Prometheus Laboratories Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NGM Biopharmaceuticals, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Metabolon, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Perspectum Ltd (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Precision Medicine Group, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grifols, S.A. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hologic, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quest Diagnostics Incorporated (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biopredictive (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments